Want to see MLEC full AI Analyst Report?
MLEC Stock Chart & Stats
$8.93
-$0.04(-4.25%)
At close: 4:00 PM EST
$8.93
-$0.04(-4.25%)
Day’s Range― - ―
52-Week Range$3.08 - $38.55
Previous CloseN/A
Volume11.69K
Average Volume (3M)209.37K
Market Cap
$5.23M
Enterprise Value$251.75M
Total Cash (Recent Filing)$1.93M
Total Debt (Recent Filing)$22.09M
Price to Earnings (P/E)―
Beta-0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding726,118
10 Day Avg. Volume506,476
30 Day Avg. Volume209,369
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.12
P/FCF Ratio-1.35
Enterprise Value/Market Cap48.15
Enterprise Value/Revenue32.14
Enterprise Value/Gross Profit-393.66
Enterprise Value/Ebitda-48.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ImprovementA very large FY2025 revenue ramp and margin expansion to ~34% indicates real commercialization traction for Moolec’s plant-produced proteins. Sustained top-line growth with improving gross margins demonstrates product-market fit and the potential for operating leverage as fixed costs are absorbed over larger volumes.
Restored Listing & Equity CushionRegaining Nasdaq compliance and a restored positive equity balance reduces immediate delisting risk and preserves access to U.S. capital markets. This stability improves the company’s ability to raise follow-on funding and execute longer-term commercialization plans without the acute threat of forced market exit.
Proprietary Molecular Farming ModelMoolec’s molecular farming approach targets durable structural demand for alternative proteins and sustainable ingredients. Plant-based expression can scale via agricultural supply chains, offering potential cost and capacity advantages versus fermentation or cell-culture, supporting a defensible niche in agri-biotech and ingredient markets.
Bears Say
Weakened Balance Sheet & High DebtMaterial negative equity and very high borrowings constrain financial flexibility and raise refinancing and solvency risk. Persistent leverage limits capacity to fund R&D and commercialization, increases the probability of dilutive financing, and makes the business more vulnerable to funding-cost shocks over the medium term.
Ongoing Cash BurnSustained negative operating and free cash flow implies continued reliance on external funding to sustain operations. Unless the company converts recent revenue momentum into positive cash generation, ongoing burn will pressure liquidity, necessitate capital raises, and potentially interrupt strategic initiatives or slow commercialization.
Legal & Governance RiskActive winding-up litigation tied to historic fees is a structural governance and creditor-risk issue. It can block corporate distributions, consume management time, impair relationships with advisers, and complicate financing or corporate actions. The dispute highlights legacy governance and potential contingent liabilities.
Moolec Science News
MLEC FAQ
What was Moolec Science’s price range in the past 12 months?
Moolec Science lowest stock price was $3.08 and its highest was $38.55 in the past 12 months.
What is Moolec Science’s market cap?
Moolec Science’s market cap is $5.23M.
When is Moolec Science’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Moolec Science’s earnings last quarter?
Currently, no data Available
Is Moolec Science overvalued?
According to Wall Street analysts Moolec Science’s price is currently Overvalued.
Does Moolec Science pay dividends?
Moolec Science does not currently pay dividends.
What is Moolec Science’s EPS estimate?
Moolec Science’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moolec Science have?
Moolec Science has 726,118 shares outstanding.
What happened to Moolec Science’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Moolec Science?
Currently, no hedge funds are holding shares in MLEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moolec Science
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.
Technical Analysis
AIM ImmunoTech
―
Ensysce Biosciences
―
Cyclerion Therapeutics
―
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
― Other Institutional Investors
99.99% Public Companies and
Individual Investors